CurrentProvidence Health PlanPolicy 60

Sleep Disorder Testing (facility-based polysomnography, MSLT/MWT)

Customize your policy alerts

Sign up for Providence Health Plan Policy 60 alerts

Get alerted when Policy 60 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines medical necessity and coverage criteria for facility-based polysomnography (including split-night and full-night studies), positive airway pressure titration, multiple sleep latency/maintenance of wakefulness testing, repeat studies, and non-covered sleep testing for Providence Health Plan members.

Policy Summary

PayerProvidence Health Plan

PolicySleep Disorder Testing (facility-based polysomnography, MSLT/MWT)

Policy CodePolicy 60

Change TypeMinor / annual review

Effective DateJul 1, 2026

Last ReviewJul 1, 2026

Next Review DateJun 1, 2027

Key ActionObtain prior authorization for facility-based polysomnography (initial PA covers either full-night diagnostic PSG or PSG with CPAP titration) and document intended study type; request retroactive review if the study plan changes.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

14criteria sections

ESS >=10ESS threshold

24 hrsPSG before MSLT

Insufficient evidence

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentProvidence Health PlanPolicy 60

Sleep Disorder Testing (facility-based polysomnography, MSLT/MWT)

Customize your policy alerts

Sign up for Providence Health Plan Policy 60 alerts

Get alerted when Policy 60 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerProvidence Health Plan

PolicySleep Disorder Testing (facility-based polysomnography, MSLT/MWT)

Policy CodePolicy 60

Change TypeMinor / annual review

Effective DateJul 1, 2026

Last ReviewJul 1, 2026

Next Review DateJun 1, 2027

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

14criteria sections

ESS >=10ESS threshold

24 hrsPSG before MSLT

Insufficient evidence

95810 or 95811initial PA

Coverage Criteria for Sleep Disorder Testing

Split-Night Study (Facility-Based Polysomnography with Initiation of Positive Airway Pressure)

Split-night facility-based polysomnography with initiation of PAP

II: Facility-based polysomnography in which the initial diagnostic portion of the PSG is followed by positive airway pressure (PAP) titration (split-night) is considered medically necessary only when the applicable diagnostic criterion I is met; otherwise it is considered not medically necessary.

References requirement that criterion I be met

Full-Night Facility-Based Polysomnography to Diagnose Sleep Related Disorders

Full-night facility-based polysomnography to diagnose suspected sleep disorders

III: A full-night facility-based polysomnography may be considered medically necessary for diagnosis of suspected sleep disorders when clinical documentation indicates a split-night study is not clinically appropriate and the diagnostic criterion I is met.

Requires documentation why split-night is not clinically appropriate

Full-Night Facility-Based Polysomnography for Risk Screening in Patients with Excessive Daytime Sleepiness

Full-night PSG for risk screening in patients with unexplained excessive daytime sleepiness

IV: May be considered medically necessary when ALL of the following are met: A) the patient's safety or job performance is compromised; and B) medical conditions have been considered and treated if indicated; and C) medications are deemed noncontributory; and D) drug or alcohol misuse has been excluded; and E) at least one suspected sleep disorder is present (1. central sleep apnea or hypoventilation disorder; 2. obesity hypoventilation syndrome; 3. co-existing sleep disorder; or 4. obstructive sleep apnea).ESS >= 10

Epworth Sleepiness Scale score ≥10 defines excessive daytime sleepiness for this criterion

Full-Night Facility-Based Polysomnography for non-OSA Sleep Disorders

Full-night PSG for suspected non-OSA sleep disorders

V: A full night of facility-based polysomnography may be considered medically necessary when a comorbid sleep-related disorder other than obstructive sleep apnea is suspected (examples include hypersomnia, narcolepsy, parasomnia, and periodic limb movement disorder).

Examples are illustrative, not exhaustive

Repeat Full-Night Facility-Based Polysomnography

Repeat full-night facility-based polysomnography

A: To post-operatively assess the efficacy of OSA surgical treatment (e.g., UPPP, hypoglossal nerve stimulation).
B: Patient underwent surgical treatment for OSA or adhered to prescribed nonsurgical treatment (e.g., oral appliance or PAP) and has worsening or recurrent symptoms.
C: Assessment of treatment results on PAP therapy after substantial weight loss.>= 10% body weight
Substantial weight loss defined as ~10% of body weight
D:

Facility-Based Polysomnography for Positive Airway Pressure Titration

Facility-based polysomnography for positive airway pressure titration following a diagnostic study

VIII

A: Patient has a confirmed diagnosis of one or more of: central sleep apnea or hypoventilation disorder; obesity hypoventilation syndrome; co‑existing sleep disorder; or obstructive sleep apnea AND the patient has at least one comorbid condition expected to degrade the accuracy of home/auto titration (a. significant cardiorespiratory disease such as COPD or CHF NYHA III–IV; b. potential respiratory muscle weakness from neuromuscular conditions; c. awake hypoventilation or suspected sleep‑related hypoventilation; d. chronic opioid use; e. history of stroke; f. severe insomnia).
Comorbid conditions listed a–f
B: Patient has failed or is contraindicated for an auto‑PAP (APAP) trial.
C: Patient has failed a CPAP trial and requires BiPAP or ASV titration.

Multiple Sleep Latency Test (MSLT)/Maintenance of Wakefulness Testing

Multiple Sleep Latency Test (MSLT) or Maintenance of Wakefulness Testing (MWT)

X: MSLT or MWT may be considered medically necessary when EITHER A or B is met: A) as part of evaluation for suspected narcolepsy to confirm diagnosis and completed in conjunction with polysomnography conducted no more than 24 hours prior to MSLT; OR B) as part of evaluation for suspected idiopathic hypersomnia to help differentiate it from narcolepsy.PSG within 24 hours before MSLT

PSG must be conducted no more than 24 hours prior to MSLT

Repeat MSLT or MWT Testing

Repeat MSLT or MWT testing

XII: Repeat MSLT or MWT testing may be considered medically necessary when ANY of the following are met: A) the initial test was affected by extraneous circumstances; B) appropriate study conditions were not present during initial testing; or C) patient is suspected to have narcolepsy but earlier MSLT evaluations did not provide polygraphic confirmation.

Diagnostic modality coverage criteria

Coverage follows AASM and referenced guideline recommendations and the summarized evidence:

PSG as standard: Polysomnography is the standard diagnostic test for OSA when there is clinical concern based on a comprehensive sleep evaluation.

Supported by AASM good practice statements and evidence summary

HST covered when: Home sleep testing is covered for diagnosis of OSA in uncomplicated adult patients presenting with signs and symptoms indicating increased risk of moderate to severe OSA when a technically adequate device is used.

AASM recommendation; if single HST is negative or technically inadequate, PSG should be performed

When PSG required instead of HST: Patients with significant cardiorespiratory disease, potential respiratory muscle weakness, awake hypoventilation or suspected hypoventilation, chronic opioid use, history of stroke, or severe insomnia should have PSG rather than HST.

AASM strong recommendation

Indications for facility-based PSG

Coverage stance and clinical criteria summary

PSG as gold standard: Facility-based polysomnography (PSG) is the gold standard diagnostic test for sleep disorders and is indicated for patients with significant comorbid medical conditions (e.g., pulmonary disease, heart failure) where home sleep testing accuracy may be degraded.

Supported by AASM recommendations and evidence summary

Home sleep testing (HST) coverage

HST for OSA diagnosis: Home sleep testing (HST) is an accurate diagnostic for ruling in obstructive sleep apnea and is recommended for diagnosing OSA in appropriate patients without significant comorbidities; if a single HST is negative, inconclusive, or technically inadequate, facility‑based PSG should be performed.

AASM recommendations referenced

Actigraphy (coverage limitations)

Actigraphy limitations: Actigraphy alone is insufficient evidence for routine diagnosis of OSA and is considered not medically necessary for that purpose; it may be used to estimate total sleep time when integrated with HST or in select indications (e.g., insomnia, circadian rhythm disorders, preparation for MSLT) per guideline statements.minimum 72 hours recording recommended when used

Evidence insufficient; may supplement HST to estimate total sleep time

Split-night and follow-up PSG

Split-night and follow-up PSG: AASM recommends split‑night studies when clinically appropriate; follow‑up PSG is indicated to evaluate efficacy of certain OSA treatments, recurrent or worsening symptoms, or to assess patients on PAP therapy with significant weight loss or weight gain and return of symptoms.

Follow‑up PSG indicated per AASM

Actigraphy testing (e.g., ActiGraph, Actiware, ActiTrac, Actiwatch) for the diagnosis of sleep-related disorders is not medically necessary. The evidence summary reports no randomized controlled trials and identifies methodological limitations in available studies; actigraphy provides a gross estimate of sleep but is limited in specificity and is not a substitute for polysomnography for routine diagnosis of sleep disorders.

Sleep studies performed with devices that do not provide a measurement of apnea-hypopnea index (AHI) and oxygen saturation are considered not medically necessary for any indication. The policy and referenced guidelines require technically adequate devices (including measurement of AHI and oxygen saturation) to support diagnosis of obstructive sleep apnea, and recommend polysomnography or home sleep apnea testing with appropriate channel monitoring.

Remote-controlled titration of an oral appliance (example: MATRx; CPT 95999) is considered not medically necessary. Although preliminary studies report that remote-controlled titration can identify candidates and target protrusive positions, the evidence lacks data on long-term outcomes, impact on health outcomes, and clinical utility to support routine coverage.

U.S. Food and Drug Administration approval or clearance alone does not establish medical necessity or serve as a basis for coverage. Regulatory status is provided for informational purposes only and does not substitute for clinical evidence of effectiveness.

Actigraphy alone is not indicated for routine diagnosis of obstructive sleep apnea (OSA) due to insufficient evidence; it may be used to estimate total sleep time when integrated with a technically adequate home sleep apnea test. Home sleep testing (HST) is also not indicated for patients with significant comorbid medical conditions (for example, pulmonary disease or heart failure) where portable testing accuracy may be degraded; in such patients facility-based polysomnography is indicated.

Actigraphy for diagnosis of sleep disorders and single-night oral appliance titration (e.g., MATRx) lack sufficient high-quality evidence to support routine medical coverage. The evidence summary finds actigraphy studies limited by methodology and concludes actigraphy is insufficient as a standalone diagnostic tool; likewise, oral appliance single-night titration has no published data demonstrating long-term clinical outcomes or utility.

Split-night facility-based polysomnography in which the initial diagnostic portion is followed by PAP titration is considered not medically necessary when the policy's prerequisite criterion I is not met. Documentation must support that the split-night protocol is appropriate per the stated criteria; absent that, initiation of PAP during a split-night study is not covered.

Repeat full-night facility-based polysomnography is considered not medically necessary when the repeat-study criteria (criterion VI) are not met. Repeat PSG is only potentially covered when one or more specified indications are present (e.g., post-operative assessment of OSA surgery, recurrent/worsening symptoms after prior treatment, or assessment after substantial weight change).

Facility-based polysomnography for positive airway pressure (PAP) titration following a diagnostic study is considered not medically necessary when the policy's PAP titration criteria (criterion VIII) are not met. PAP titration in-lab is reserved for patients with confirmed diagnoses and comorbid conditions that degrade home/auto titration accuracy, failed APAP/CPAP trials when advanced titration is required, or other specified limitations (e.g., impaired cognition or mobility).

Multiple Sleep Latency Test (MSLT) / Maintenance of Wakefulness Testing (MWT), and repeat MSLT/MWT, are considered not medically necessary when their respective clinical criteria (criterion X for initial testing and criterion XII for repeat testing) are not met. MSLT/MWT are covered only in well-defined circumstances such as evaluation for narcolepsy with a PSG conducted within 24 hours prior to MSLT, or to differentiate idiopathic hypersomnia from narcolepsy.

Actigraphy for the diagnosis of sleep disorders and single-night oral appliance titration (MATRx) are assigned insufficient evidence to support routine medical coverage. The evidence review found actigraphy studies limited in methodological quality and no long-term outcomes data for remote-controlled oral appliance titration; therefore these modalities are excluded from routine coverage.

Routine use of actigraphy alone for the diagnosis of obstructive sleep apnea is considered not medically necessary based on insufficient evidence. The AASM and evidence summary note actigraphy may supplement HST to estimate total sleep time in specific situations, but it should not be used as a standalone diagnostic test for OSA.

Coding and Code Tables

Non-covered / not medically necessary examplesCPTNot Covered

95999

Remote-controlled titration of an oral appliance (example cited as CPT: 95999) — considered not medically necessary

PSG monitor Type classifications (operational signals/channels)mixed

No codes listed

Device/FDA identifiersmixed

DEN170090

FDA designation referenced for MATRx Plus auto titration device (FDA document identifier)

Device product codes (informational)mixed

MNR	FDA 510(k) product code referenced for home sleep testing devices

Device product codes (informational)mixed

QCJ	FDA classification product code referenced for MATRx Plus remote-controlled mandibular titration device
GWQ	FDA 510(k) product code referenced for in‑lab polysomnography devices

Facility and home sleep study CPT codesCPT

95810	Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist.
95811	Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy (CPAP) - includes split-night or titration.
95800	Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (eg, by airflow or peripheral arterial tone), and sleep time.
95801	Sleep study, unattended, simultaneous recording; minimum of heart rate, oxygen saturation, and respiratory analysis (eg, by airflow or peripheral arterial tone).
95803	Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording).
95806	Sleep study, unattended, simultaneous recording of heart rate, oxygen saturation, respiratory airflow, and respiratory effort (eg, thoracoabdominal movement).
95999	Unlisted neurological or neuromuscular diagnostic procedure.

HCPCS home sleep testing codesHCPCS

G0398	Home sleep study test (HST) with type II portable monitor, unattended; minimum of 7 channels: EEG, EOG, EMG, ECG/heart rate, airflow, respiratory effort and oxygen saturation.
G0399	Home sleep test (HST) with type III portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ECG/heart rate and 1 oxygen saturation.
G0400	Home sleep test (HST) with type IV portable monitor, unattended; minimum of 3 channels.

Epworth Sleepiness Scale (ESS) threshold used in criteria

ESS thresholdEpworth Sleepiness Scale (ESS) score of 10 or greater defines excessive daytime sleepiness for full‑night PSG risk screening.

Use in criteriaESS ≥10 is required as the EDS threshold in the full‑night PSG risk‑screening criterion (criterion IV).

ContextApplied when unexplained excessive daytime sleepiness is present and other required clinical criteria (A–E) are met.

Substantial weight change threshold for repeat PSG

Substantial weight change thresholdDefined as 10% of body weight (either loss or gain) as a trigger for repeat PSG assessment on PAP therapy.

Provider Actions, Prior Authorization, and Billing Rules

Note

Benefit application

This policy applies to Commercial and Medicaid/OHP products. Medicare members are handled by a separate Medicare policy when specified.

Prior Authorization

Prior authorization for in‑lab studies and specialized titration

Prior authorization may be required for facility-based polysomnography (including split-night studies) and for specialized titration modalities (for example, remote mandibular titration like MATRx Plus).

Prior Authorization

Prior authorization: when facility‑based PSG is indicated versus HST

Facility-based PSG (in-lab) is indicated rather than HST for patients with significant comorbid medical conditions (e.g., pulmonary disease, heart failure) or other conditions expected to degrade HST accuracy; prior authorization should reflect this distinction.

Background and Evidence Summary

Polysomnography (PSG) is the diagnostic gold standard for assessing respiratory events, oxygen saturation, sleep staging, and arousals when evaluating sleep-related disorders including obstructive and central sleep apnea, hypoventilation syndromes, and other sleep disorders. PSG provides multi-channel physiologic monitoring required to measure apnea-hypopnea index (AHI), oxygen desaturation, sleep stages, and arousals—parameters essential to diagnose and characterize sleep-disordered breathing. When home sleep testing is inappropriate or technically inadequate, facility-based PSG is indicated.

Definitions and Clinical Thresholds

Definition — Apnea

DefinitionApnea: the cessation of airflow for at least 10 seconds.

Clinical relevanceUsed in calculation of AHI/RDI to define severity of sleep‑disordered breathing.

Source referenceTerm defined in the policy's definitions section (MP60).

Definition — Apnea-hypopnea index (AHI)

DefinitionApnea‑hypopnea index (AHI): the number of apnea and hypopnea events per hour of sleep; used to indicate the severity of sleep apnea.

Related metricRespiratory disturbance index (RDI) includes apneas, hypopneas, plus RERAs per hour of sleep.

Policy Revision History

2026-07-01Policy Effective DateLatest

Policy effective date set to July 1, 2026 with associated review schedule (last review 06/2026, next review 06/2027).

2024-08-01Annual Review

Annual review with minor formatting updates and update to excessive daytime sleepiness (EDS) criteria.

2023-07-01Annual Update

Policy Summary

PayerProvidence Health Plan

PolicySleep Disorder Testing (facility-based polysomnography, MSLT/MWT)

Policy CodePolicy 60

Change TypeMinor / annual review

Effective DateJul 1, 2026

Last ReviewJul 1, 2026

Next Review DateJun 1, 2027

SourceLink

On This Page

Assessment of OSA patients on PAP therapy after substantial weight gain with return of symptoms.

Substantial weight gain defined as ~10% of body weight

D: Patient has impaired cognition or mobility limiting ability to operate home/auto titration equipment.

Negative/inconclusive HST follow-up: If a single home sleep apnea test is negative, inconclusive, or technically inadequate, facility-based polysomnography should be performed.

AASM strong recommendation

Actigraphy stance: Evidence is insufficient to support actigraphy alone for routine diagnosis of OSA; actigraphy may be integrated with HST to estimate total sleep time when no alternative objective measurement is available.

AASM conditional recommendation

Oral appliance titration (MATRx): Remote‑controlled oral appliance titration (e.g., MATRx) has insufficient evidence of long‑term outcomes and clinical utility and is considered investigational/ not medically necessary for routine use.

Evidence summary notes insufficient long‑term outcomes

Repeat PSG indicationsApplied to assess treatment results after substantial weight loss or to reassess after substantial weight gain with return of symptoms (criterion VI.C and VI.D).

Documentation noteClinical documentation should link the 10% weight change to change in symptoms or treatment response to justify repeat PSG.

PSG must be performed within this time before MSLT

PSG timing before MSLTPolysomnography must be conducted no more than 24 hours prior to the Multiple Sleep Latency Test (MSLT).

PurposeEnsures MSLT is interpreted in conjunction with a recent overnight PSG when evaluating suspected narcolepsy (criterion X.A).

Coverage implicationMSLT is considered medically necessary only when completed with a PSG within the 24‑hour window or when other criterion X conditions are met.

AHI/RDI severity thresholds and OHS criteria (BMI and PaCO2)

AHI/RDI severity thresholdsMild: AHI/RDI 5–14; Moderate: AHI/RDI 15–30; Severe: AHI/RDI >30.

OHS obesity criterionBody mass index (BMI) > 30 kg/m2 is part of the definition for obesity hypoventilation syndrome (OHS).

OHS hypercapnia criterionDaytime arterial hypercapnia with PaCO2 >45 mm Hg is required for OHS diagnosis (with BMI >30 kg/m2).

Actigraphy recording duration (minimum/typical range)

Minimum recording durationActigraphy testing requires a minimum of 72 hours of recording.

Typical maximum/typical rangeRecording may extend up to 14 consecutive days (72 hours to 14 days is the stated range for CPT 95803).

Use in evaluationActigraphy may be integrated with HST to estimate total sleep time when alternative objective measures are not available, but is insufficient alone for routine OSA diagnosis.

Prior Authorization

Initial prior authorization covers CPT 95810 or 95811

Initial prior authorization approval is for either CPT 95810 (full-night diagnostic PSG without CPAP titration) or CPT 95811 (PSG with CPAP titration or split-night); any additional sleep disorder testing requires submission of a new prior authorization.

Select the appropriate code (95810 or 95811) based on the planned study.
If the study plan changes unexpectedly, request a retroactive authorization review rather than billing both codes.

Step Therapy

PAP titration sequencing — when in‑lab titration is required

Facility-based PAP titration may be required when the patient has failed or is contraindicated for an APAP trial, has failed CPAP and requires BiPAP/ASV titration, or meets other criterion VIII indications (e.g., confirmed diagnoses with comorbidities expected to degrade home/auto titration).

Comply with criterion VIII subcriteria (A–D) when documenting need for in‑lab titration.

Documentation Required

Document stepwise testing and rationale before titration

Document prior diagnostic testing and the clinical rationale before proceeding to in‑lab PAP titration or oral appliance titration (e.g., PSG‑confirmed OSA before PAP titration or RCMP/MATRx Plus titration).

Include evidence of prior diagnostic study results and reasons why home/auto titration is unsuitable when applicable.

Step Therapy

Step from HSAT to PSG after negative/inconclusive/technically inadequate HSAT

If a single home sleep apnea test (HSAT) is negative, inconclusive, or technically inadequate, perform facility-based PSG before concluding absence of OSA.

Failure to obtain follow-up PSG when indicated may risk coverage denial.

Note

No action specified

Placeholder callout — no requirement text provided in the source brief to populate this block.

Documentation Required

Document why a full‑night PSG is necessary (when split‑night inappropriate)

When clinical documentation demonstrates a split‑night study is not clinically appropriate, include that rationale to support medical necessity for a full‑night PSG.

State specific reasons why split‑night protocol would be inadequate for diagnostic or titration purposes.

Documentation Required

Required clinical documentation (AHI/RDI, ESS, MSLT/MWT results)

Required diagnostic documentation must include objective test results and relevant measures such as AHI or RDI and Epworth Sleepiness Scale (ESS) score; include MSLT/MSLT trial results when applicable to support testing and medical necessity.

AHI/RDI values
Epworth Sleepiness Scale (ESS) score (ESS ≥ 10 indicates excessive daytime sleepiness)
MSLT results (4–5 nap trials) or MWT results when applicable

Documentation Required

Comprehensive sleep evaluation and follow‑up required

Perform diagnostic testing for OSA only after a comprehensive sleep evaluation and ensure adequate follow‑up; document the clinical evaluation and any comorbidities that would mandate in‑lab PSG.

Include clinical history, examination findings, and follow‑up plan.
Document comorbid conditions that necessitate in‑lab PSG (e.g., cardiorespiratory disease, neuromuscular weakness).

Prior Authorization

Prior authorization: indicate intended study type and request retro review if plan changes

Indicate the intended study type (PSG vs split‑night vs titration-only) during prior authorization; if the planned study changes, request a retroactive authorization review rather than billing both PSG codes.

Clearly state the planned CPT code (95810 or 95811) on the PA request.

Denial Risk

Denial risk — repeat PSG not medically necessary without meeting repeat criteria

Repeat facility‑based polysomnography is considered not medically necessary when the repeat study criteria (criterion VI) are not met.

Ensure one of criteria A–D in VI is documented to justify repeat PSG (e.g., post‑operative assessment, recurrent symptoms, substantial weight change ≥10%).

Denial Risk

Denial risk — PAP titration considered not medically necessary if criterion VIII not met

Facility‑based PSG for PAP titration will be denied as not medically necessary if the patient does not meet the indications listed in criterion VIII.

Document which subcriterion (A–D) of criterion VIII applies when requesting in‑lab titration.

Billing Rule

Device classification and signal requirements affect study classification and coverage

Use of monitors that do not meet the Type I–IV signal/channel classification may lead to misclassification of studies and could impact coverage determinations.

Confirm device meets Type I–IV operational signal/channel criteria when reporting study type.

Denial Risk

HST contraindications — patients with significant comorbidities should have PSG

Home sleep testing is inappropriate (and may be denied) for patients with significant comorbid medical conditions such as pulmonary disease or heart failure where portable testing accuracy is degraded.

Refer such patients for facility‑based PSG.

Step Therapy

Follow‑up testing after inadequate HSAT — perform facility PSG

If a single HSAT is negative, inconclusive, or technically inadequate, facility‑based PSG is recommended; failure to obtain follow‑up PSG when indicated may risk denial.

Document HSAT limitations and rationale for proceeding to PSG.

Billing Rule

Mutually exclusive PSG codes — do not bill 95810 and 95811 together

CPT codes 95810 and 95811 are mutually exclusive and should not be billed together on the same claim; billing both together may result in a denial.

If split‑night was intended, bill only 95811; if diagnostic night then separate PA required for subsequent titration (95811).

Billing Rule

Unlisted code submission — denials for non‑covered uses; PA recommended for potentially covered uses

Unlisted codes submitted for services that this policy describes as non‑covered will be denied as not covered; unlisted codes for potentially covered services are reviewed but prior authorization is recommended to avoid post‑service denial.

Obtain prior authorization for unlisted codes related to potentially covered services to reduce risk of denial.

AHI/RDI thresholds are used to classify OSA severity (mild/moderate/severe).

Definition — Epworth Sleepiness Scale (ESS)

DefinitionEpworth Sleepiness Scale (ESS): a self‑administered questionnaire that asks respondents to rate their usual chances of dozing off; a score of 10 or greater indicates excessive daytime sleepiness (EDS).

Role in policyESS score ≥10 is the EDS threshold for full‑night PSG risk‑screening criteria.

AdministrationSelf‑administered instrument used to document subjective daytime sleepiness in diagnostic documentation.

Definition — Cataplexy

DefinitionCataplexy: sudden and uncontrollable muscle weakness or paralysis often triggered by strong emotion (e.g., excitement or laughter).

Clinical contextCataplexy is a key feature distinguishing narcolepsy type 1 (NT1) from NT2 and is relevant to MSLT interpretation and narcolepsy diagnosis.

Diagnostic rolePresence of cataplexy informs narcolepsy subtyping and may obviate some testing pathways in clinical evaluation.

Definition — Apnea / Hypopnea / AHI / RDI definitions

ApneaCessation of airflow ≥10 seconds.

HypopneaAbnormally slow or shallow breathing resulting in reduced airflow (policy definition).

AHI / RDIAHI = apneas + hypopneas per hour of sleep; RDI = apneas + hypopneas + RERAs per hour of sleep.

Definition — Severity of OSA — Mild/Moderate/Severe AHI/RDI thresholds

Mild OSAAHI or RDI 5–14 events per hour.

Moderate OSAAHI or RDI 15–30 events per hour.

Severe OSAAHI or RDI greater than 30 events per hour.

Definition — Epworth Sleepiness Scale (duplicate definition entry)

ESS (duplicate entry)Epworth Sleepiness Scale: self‑administered questionnaire; score ≥10 indicates excessive daytime sleepiness.

Policy useReferenced in full‑night PSG screening criteria to define EDS (ESS ≥10).

InterpretationScores are used in clinical documentation supporting need for diagnostic testing.

Definition — Narcolepsy types NT1/NT2

NT1 (narcolepsy type 1)Narcolepsy type 1 (NT1) is associated with cataplexy or low hypocretin‑1; formerly 'narcolepsy with cataplexy.'

NT2 (narcolepsy type 2)Narcolepsy type 2 (NT2) lacks cataplexy and low hypocretin‑1; may be reclassified to NT1 if cataplexy develops or hypocretin‑1 falls.

Epidemiology noteNT1 is more common than NT2; conversion from NT2 to NT1 occurs in about 10% of cases.

Definition — Obesity hypoventilation syndrome (OHS) criteria (BMI and PaCO2)

OHS BMI criterionObesity hypoventilation syndrome (OHS) is typically defined as BMI > 30 kg/m2 in combination with daytime hypercapnia.

OHS PaCO2 criterionDaytime arterial hypercapnia with PaCO2 >45 mm Hg is required (not explained by other causes) for OHS diagnosis.

Clinical overlapSymptoms may overlap with OSA (e.g., morning headaches, EDS); both criteria (BMI and PaCO2) are needed for OHS identification.

Definition — Home Sleep Testing (HST) definition

DefinitionHome Sleep Testing (HST): unattended portable sleep testing devices (FDA product code MNR) cleared under 510(k) used to diagnose OSA in appropriate outpatient populations.

Appropriate useRecommended for diagnosing OSA in selected patients without significant comorbidities per AASM guidance; not for patients where comorbidities may degrade accuracy.

Device referencePolicy references FDA product code MNR for HST devices.

Definition — Polysomnography (PSG) definition

DefinitionPolysomnography (PSG): facility‑based attended sleep study devices (FDA product code GWQ) considered the diagnostic gold standard for sleep disorders.

ComponentsPSG includes multi‑channel physiologic monitoring (sleep staging, respiratory events, oxygen saturation, arousals) and is the standard when comorbidities may degrade HST accuracy.

Evidence basisAASM recognizes PSG as the gold standard and recommends PSG when HST is inappropriate or when HST is negative/inconclusive.

Definition — Actigraphy definition

DefinitionActigraphy: wearable devices that estimate sleep parameters (wrist‑worn activity monitoring) used to estimate sleep/wake patterns and total sleep time.

LimitationsLimited specificity and insufficient evidence to be a substitute for PSG for routine OSA diagnosis; may supplement HST to estimate total sleep time when no alternative objective measurement is available.

Recording duration (coding link)CPT 95803 specifies a recording range of minimum 72 hours to 14 consecutive days.

Definition — Oral appliance titration (remote-controlled/MATRx) definition

DefinitionOral appliance titration (remote‑controlled/MATRx): techniques to titrate mandibular advancement devices remotely to identify candidates and target protrusive positions.

Evidence gapStudies show promising diagnostic validity for candidate selection and target position prediction, but no published data on long‑term outcomes or clinical utility.

Coverage stanceSingle‑night remote oral appliance titration (e.g., MATRx) lacks sufficient evidence for routine coverage per the policy.

Definition — Facility-based polysomnography (PSG) definition (duplicate/expanded)

DefinitionFacility‑based polysomnography (PSG): full‑night laboratory sleep study considered the diagnostic gold standard; includes multi‑channel physiologic monitoring and technologist attendance.

IndicationsIndicated for patients with significant comorbid medical conditions where HST accuracy may be degraded, for split‑night studies when appropriate, and for follow‑up testing per AASM guidance.

FDA product codePolicy references FDA product code GWQ for in‑lab PSG devices.

Definition — Home sleep testing (HST) definition (duplicate/expanded)

DefinitionHome sleep testing (HST): an unattended sleep study performed at home using portable monitors (FDA product code MNR); appropriate for diagnosing OSA in selected patients without significant comorbidities.

LimitationsNot indicated for patients with significant cardiorespiratory disease, potential respiratory muscle weakness, awake hypoventilation, chronic opioid use, history of stroke, or severe insomnia.

Follow‑upIf a single HST is negative, inconclusive, or technically inadequate, facility‑based PSG should be performed per AASM recommendation.

Definition — Actigraphy definition (duplicate/expanded)

DefinitionActigraphy: wrist‑worn activity monitoring used to estimate sleep/wake patterns; insufficient alone for OSA diagnosis but may supplement HST to estimate total sleep time.

EvidenceNo systematic review or RCTs establish actigraphy for diagnosis; technical validity studies show limited specificity compared with PSG.

Recording rangePolicy coding references a recording range of minimum 72 hours to 14 consecutive days for actigraphy CPT code 95803.

Annual update including change of denial language for actigraphy testing to 'not medically necessary' and related administrative code configuration.

2023-02-01Template Conversion

Converted policy to new policy template.

2024-03-01Interim Update

Interim update with minor criteria changes and billing guideline additions noted in subsequent annual update entries.

2025-07-01Annual Update

Annual update with minor formatting changes and addition of billing guideline.